CRISPR Therapeutics AG (CRSP) AI Stock Analysis

CRISPR Therapeutics AG is a pioneering gene editing company headquartered in Zug, Switzerland, focused on advancing gene-based therapies for serious diseases using its proprietary CRISPR/Cas9 platform. This technology enables precise modifications to genomic DNA. Its portfolio covers hemoglobinopathies, oncology, regenerative medicine, and rare diseases. Leading initiatives include CTX001, an ex vivo gene-edited therapy designed to treat transfusion-dependent beta-thalassemia and severe sickle cell disease. It is also advancing gene-edited allogeneic CAR-T therapies such as CTX110, CTX120, and CTX130, as well as VCTX210 for type 1 diabetes and in vivo programs targeting liver, lung, muscle, and central nervous system disorders. Key strategic partners include Bayer Healthcare LLC and Vertex Pharmaceuticals Incorporated.

Revenue has exhibited wide variance tied to collaboration milestones. After reaching $913.1M in FY2021 with net income of $377.7M, revenue fell to $436,000 in FY2022 before rebounding to $370.0M in FY2023. In FY2024, revenue fell 90.5% to $35.0M, followed by a 90.0% decline in FY2025 to $3.5M, generating a net loss of -$581.6M and an operating margin of -16191.4%. Operating margin for the trailing twelve months was -1127.5% on revenue of $13.4M. However, in the latest quarter ending June 30, 2026, quarterly revenue grew 1041.4% year-over-year. Research and development expense stood at $265.3M in FY2025.

As of June 30, 2026, CRISPR Therapeutics held $2.36B in cash and short-term investments and $783.7M in total debt, resulting in net cash of $1.58B. Shareholders' equity was $1.75B and the current ratio was 17.85. In FY2025, free cash flow was -$345.9M and capital expenditures were $914,000. Cash was supplemented by $71.3M in share issuance during FY2025, contributing to a 5-year share count increase of 25.9%.

CRISPR Therapeutics has a market capitalization of $4.76B and an enterprise value of $3.81B. It trades at a forward P/E of 23.4x, higher than the 17.3x median of its US-listed Healthcare peers. Its price-to-sales ratio is 355.6x, compared to the peer median of 4.1x, and its EV/EBITDA is 14.2x versus the peer median of 12.0x. Over the past year, the stock returned -28.0%, trailing the S&P 500 (SPY) return of 16.8%. Over 5 years, the stock returned -49.2% while the S&P 500 gained 83.0%.

Wall Street analysts hold 8 Strong Buy, 5 Buy, and 10 Hold ratings, with 0 Sell ratings. The mean price target is $85.63, representing an upside of 73.9% from the last close of $49.25 on October 16, 2026. For the fiscal year ending December 31, 2026, analysts estimate an EPS of -$4.45 on revenue of $40.4M. For FY2027, 19 analysts project revenue of $151.2M and an EPS of -$3.55. The company beat EPS estimates in 2 of the last 4 quarters, and its next earnings date is November 9, 2026.

This page is an AI-written research summary of CRISPR Therapeutics AG (CRSP). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: CRSP income statement, CRSP balance sheet, CRSP key metrics, CRSP analyst forecast, CRSP chart. See the CRSP stock overview for the latest quote and news.